tbuckley/cabot-search huggingface dataset:
MA09.03 Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226
Authors: Rosalyn Juergens, Desiree Hao, Scott Laurie, Mihaela Mates, Mustapha Tehfe, Penelope Bradbury, Christian Kollmannsberger, Peter Ellis, John Hilton, Pamela Brown-Walker, Lesley Seymour
Journal: Journal of Thoracic Oncology (2017)
MSMD Patients with IFN-g-STAT1 Signaling Defect Present Enhanced Osteoclastogenesis and Bone Resorption
Authors: Shiho Nishimura, Miyuki Tsumura, Osamu Hirata, Reiko Kagawa, Yoko Mizoguchi, Satoshi Okada, Masao Kobayashi
Journal: Blood (2015)
P174 Effect of continued treatment with pirfenidone following a ≥10% relative decline in percent predicted forced vital capacity (%FVC) in patients with idiopathic pulmonary fibrosis (IPF)
Authors: AU Wells, C Albera, U Costabel, I Glaspole, MK Glassberg, L Lancaster, DJ Lederer, CA Pereira, JJ Swigris, B-M Day, W Chou, SD Nathan
Journal: Thorax (2016)

<h3>Background</h3> The variability in disease progression in patients with IPF complicates the assessment of treatment response. Previously a pooled analysis of three Phase 3 trials showed that patients who experienced a ≥10% <i>absolute </i>decline in %FVC during the first 6 months of treatment derived a clinical benefit with continued pirfenidone treatment in the subsequent 6 months [Nathan <i>et al</i>. <i>ATS</i> 2015]. To further explore the potential benefit of continued pirfenidone treatment in patients who initially experienced more modest declines, we assessed subsequent outcomes after a ≥ 10% <i>relative </i>decline in %FVC during the first 6 months of treatment. <h3>Methods</h3> Source data included all patients randomised to receive pirfenidone 2403 mg/d or placebo in the ASCEND or CAPACITY trials (N = 1247). All patients with a ≥10% relative decline in%FVC were selected by the 6-month study visit. The proportion of patients in the pirfenidone and placebo groups who experienced any of the following during the subsequent 6-month interval were compared: (1) ≥10% relative decline in%FVC or death; (2) death; or (3) no further decline in %FVC. <h3>Results</h3> Of the pooled patients that experienced an initial ≥10% relative decline in %FVC, 80 and 140 patients received pirfenidone and placebo, respectively. In the subsequent 6 months, 17 (21.3%) and 50 (35.7%) patients, respectively, experienced a ≥ 10% relative decline in %FVC or death. In addition, more patients in the pirfenidone group had no further decline in %FVC and fewer patients died compared with placebo during the subsequent 6-month interval (<b>Table 1</b>). <h3>Conclusions</h3> In patients who experienced a ≥10% relative decline in %FVC during the first 6 months of treatment, continued treatment with pirfenidone appeared to lower the risk of %FVC decline or death during the subsequent 6 months, similar to previous results observed with a ≥10% absolute %FVC cut-off. Using relative change to calculate a ≥10% initial FVC decline identified more than twice as many patients compared to using absolute change. These findings suggest a potential benefit to continued treatment with pirfenidone despite an initial clinically meaningful decline in FVC ≥10% regardless of calculation method.
P82 Outcomes for patients with negative scans on the ‘straight to CT’ pathway
Authors: H Gundersen, A Hufton, R Trafford, MJ Walshaw, M Ledson
Journal: Thorax (2016)

<h3>Introduction</h3> Liverpool has a ‘straight to CT’ service for patients with coded radiology suspicious of lung cancer and for clinicians worried symptoms may indicate malignancy. In our pathway the lung cancer team automatically take patients whose CT suggests lung cancer. For patients whose scan does not suggest cancer the result is forwarded to their GP to act upon as necessary. We have investigated the outcomes for this patient group for the calendar year 2015. <h3>Method</h3> 387 CT scans were carried out on the 72 hour ‘straight to CT’ pathway. The cancer services took 179 patients. We have reviewed local radiology, result datasets and hospital records for the remaining 208 patients whose CT results were managed by their GP. <h3>Results</h3> Within the group without suggestions of cancer on CT, indications for 72 hour CT were: 90 patients (43%) had coded radiology and 118 ‘worried clinician’ (57%) (23% haemoptysis; 34% other symptoms). The results of the CT scans showed 42 (20%) nodules requiring follow up, 49 (23.5%) inflammatory changes, 49 (23.5%) nil significant, 20 (10%) emphysema, 11 (5%) bronchiectasis and 37 (18%) combinations of other (fibrosis, PE, atelectasis etc). For follow up 17 (8%) were already under the care of a chest physician, 74 (36%) were referred to a chest physician and 117 (56%) were managed in primary care. 73 patients (35.1%) had repeat CT scans. In total 99 scans have been done, 31.3% of these were ordered by primary care 68.7% by secondary care. 4 patients following repeat imaging were diagnosed with cancer. 3 of these had nodules initially, 1 had inflammatory shadowing. <h3>Conclusion</h3> The ‘straight to CT’ pathway dictates that all patients with a CT scan not suggestive of lung cancer remain under the care of the referring clinician. Only 35% of patients subsequently needed referral for secondary care advice. The ‘straight to CT’ service not only provides prompt action for patients with cancer but empowers primary care to manage non- malignant diseases. Patients are now managed in the most appropriate setting and inappropriate hospital visits minimised.
P3.02c-005 MET Exon 14 Skipping in Quintuple-Negative (EGFR-/KRAS-/ALK-/ROS1-/RET-) Lung Adenocarcinoma
Authors: Seung Eun Lee, Geun Dong Lee, Doo-Yi Oh, Yoon-La Choi
Journal: Journal of Thoracic Oncology (2017)
Exome Sequencing of Late Recurrence T-Cell Acute Lymphoblastic Leukemia in Children Confirms Second Leukemia and Exposes Predisposition Candidate Genes
Authors: Esmé Waanders, Vincent H.J. van der Velden, Tomasz Szczepanski, Lisenka E.L.M. Vissers, Joep de Ligt, Christian Gilissen, Anke A.H. van Dijk, Simon V. van Reijmersdal, Peter M. Hoogerbrugge, Ad Geurts van Kessel, Jacques J.M. van Dongen, Roland P. Kuiper
Journal: Blood (2011)
S11 Decreased anti-inflammatory potential of mesenchymal stem cells after prolonged in vitro expansion will impact on their use as a therapy for acute respiratory distress syndrome
Authors: M Aslani, RY Mahida, A Scott, DR Thickett
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Mesenchymal stem cells (MSC) have well-established anti-inflammatory properties and could potentially be used therapeutically in Acute Respiratory Distress Syndrome (ARDS).<sup>1</sup> MSC conditioned medium (MSC-CM) has been found to reproduce the beneficial effects of MSCs.<sup>2</sup> However, the impact of expansion on MSC secretome remains elusive. In the present study we assessed the expression of four potent MSC paracrine factors after prolonged <i>in vitro</i> culture, while investigating the effects of passaging on the <i>in vitro</i> properties of MSCs. <h3>Methods</h3> Human Bone marrow-derived MSCs were expanded <i>in vitro </i>in αMEM with 16% FBS. Conditioned medium was collected from each passage and stored at −40°C. Scratch assays were undertaken using A549 cells treated with MSC-CM and control media. Proliferation of A549 cells was assessed via BrdU assay. Gene expression of expanded MSCs was assessed by RT-qPCR. VEGF and Angiopoietin in the MSC-CM were quantified by ELISA. <h3>Results</h3> RT-qPCR revealed that MSCs express the anti-inflammatory genes <i>PTGES2</i>, <i>FGF7</i> and <i>ANGPT1</i>. The expression of these genes doubled after 8 days in culture and subsequently decreased. (P &lt; 0.0005, one way Anova, n = 2). The secretion of Angiopoietin and VEGF decreased with prolonged expansion (Figure 1). MSC-CM obtained after 8 days of culture induced more efficient wound healing compared to MSC-CM obtained following prolonged expansion (P &lt; 0.005, one way Anova, n = 2). However, MSC-CM failed to affect the proliferation of A549 cells. <h3>Conclusion</h3> We conclude that MSCs of early passages are more potent angiogenic inducers, while promoting wound healing in vitro. Thus, we provide important insights into the changes occurring after prolonged <i>in vitro</i> expansion, underlining the importance of using low passage MSCs in clinical trials for ARDS. In agreement with published data, we also found that MSCs do not induce cellular proliferation in the absence of stimulation. <h3>References</h3> Antunes MA, <i>et al</i>. Mesenchymal stem cell trials for pulmonary diseases. <i>J Cell Biochem</i> 2014;<b>115</b>:1023–1032. Kordelas L, <i>et al</i>. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. <i>LeukaemiaLeukemia</i> 2014;<b>28</b>:970–973.
Retrospective Analysis of the Safety and Efficacy of Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Hematologic Malignancies
Authors: Michelle A. Fanale, Nancy L. Bartlett, Andres Forero-Torres, Anas Younes, Robert W. Chen, Jonathan W. Friedberg, Jeffrey V. Matous, Andrei R. Shustov, Scott E. Smith, Jasmine Zain, Megan M. O'Meara, Ajay K. Gopal
Journal: Blood (2012)
Incidence and Biologic Features of 5q Deletion and 5q- Syndrome in Myelodysplastic Syndrome in Korea; According to Reclassification of Myelodysplastic Syndrome by WHO 2008.
Authors: Hye Ryun Lee, Dae Sik Hong, Dae Young Zang, Hong Ghi Lee, Hwi-Joong Yoon, Hyeoung-Joon Kim, Inho Kim, Jae-Sook Ahn, Jong-Seok Lee, June-Won Cheong, Kyung-A Lee, Soo-Mee Bang, Su Yon Park, Yeo Min Yun, Yoo-Hong Min, You Kyung Lee, Dong Soon Lee
Journal: Blood (2009)
Pilot study of mobile phone technology in allergic rhinitis in European countries: the <scp>MASK</scp>‐rhinitis study
Authors: J. Bousquet, D. P. Caimmi, A. Bedbrook, M. Bewick, P. W. Hellings, P. Devillier, S. Arnavielhe, C. Bachert, K. C. Bergmann, G. W. Canonica, N.H. Chavannes, A. A. Cruz, R. Dahl, P. Demoly, G. De Vries, E. Mathieu‐Dupas, A. Finkwagner, J. Fonseca, N. Guldemond, T. Haahtela, B. Hellqvist‐Dahl, J. Just, T. Keil, L. Klimek, M. L. Kowalski, M. Kuitunen, P. Kuna, V. Kvedariene, D. Laune, A. M. Pereira, P. Carreiro‐Martins, E. Melén, M. Morais‐Almeida, J. Mullol, A. Muraro, R. Murray, L. Nogueira‐Silva, N. G. Papadopoulos, G. Passalacqua, F. Portejoie, D. Price, D. Ryan, B. Samolinski, A. Sheikh, V. Siroux, O. Spranger, A. Todo Bom, P. V. Tomazic, A. Valero, E. Valovirta, A. Valiulis, O. VandenPlas, S. van der Meulen, M. van Eerd, M. Wickman, T. Zuberbier
Journal: Allergy (2017)

The use of Apps running on smartphones and tablets profoundly affects medicine. The MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) App (Allergy Diary) assesses allergic rhinitis symptoms, disease control and impact on patients' lives. It is freely available in 20 countries (iOS and Android platforms).To assess in a pilot study whether (i) Allergy Diary users were able to properly provide baseline characteristics (ii) simple phenotypic characteristics based upon data captured by the Allergy Diary could be identified and (iii) information gathered by this study could suggest novel research questions.The Allergy Diary users were classified into six groups according to the baseline data that they entered into the App: (i) asymptomatic; (ii) nasal symptoms excluding rhinorrhea; (iii) rhinorrhea; (iv) rhinorrhea plus 1-2 nasal/ocular symptoms; (v) rhinorrhea plus ≥3 nasal/ocular symptoms; and (vi) rhinorrhea plus all nasal/ocular symptoms.By 1 June 2016, 3260 users had registered with the Allergy Diary and 2710 had completed the baseline questionnaire. Troublesome symptoms were found mainly in the users with the most symptoms. Around 50% of users with troublesome rhinitis and/or ocular symptoms suffered work impairment. Sleep was impaired by troublesome symptoms and nasal obstruction.This is the first App (iOS and Android) to have tested for allergic rhinitis and conjunctivitis. A simple questionnaire administered by cell phones enables the identification of phenotypic differences between a priori defined rhinitis groups. The results suggest novel concepts and research questions in allergic rhinitis that may not be identified using classical methods.
Analysis of Structural Changes of the Factor VIII Gene: Intron 1 and 22, in Costarrican Families with Severe Haemophilia A.
Authors: Lizbeth Salazar-Sanchez, Guillermo Jimenez-Cruz, Pilar Chaverri, Winnie Schroeder, Karin Wulff, Miriam Sandoval, Guenter K.H. Auerswald, Falko H. Herrmann
Journal: Blood (2005)
MA08.01 A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma
Authors: Heather Wakelee, Vlada Melnikova, Chris Karlovich, Shirish Gadgeel, Karen Reckamp, Jonathan W. Goldman, D. Ross Camidge, Maurice Pérol, Sai-Hong Ou, Stephen Liu, Helena Yu, Mark Socinski, Tarek Mekhail, Benjamin Solomon, Ronald Natale, Gregory Otterson, Vassiliki Papadimitrakopoulou, Jean-Charles Soria, Corey Langer, Joel Neal, Darrin Despain, Sergey Yurasov, Jason Litten, Mitch Raponi, Mark Erlander, Lecia Sequist
Journal: Journal of Thoracic Oncology (2017)
Clinical and Prognostic Significance of Eosinophilia and Inv(16)/t(16;16) In Pediatric Acute Myelomonocytic Leukemia (AML-M4).
Authors: Ingrid E.M. Bank, Válerie de Haas, H. Berna Beverloo, Christian M. Zwaan, Gertjan J. Kaspers
Journal: Blood (2010)
OA03.06 Evaluation of Toxicity Profile of PD-1 versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
Authors: Rathi Pillai, Madhusmita Behera, Taofeek Owonikoko, Alice Kamphorst, Suchita Pakkala, Chandra Belani, Fadlo Khuri, Rafi Ahmed, Suresh Ramalingam
Journal: Journal of Thoracic Oncology (2017)
Novel Risk Markers and Risk Assessments for Cardiovascular Disease
Authors: Mark R. Thomas, Gregory Y.H. Lip
Journal: Circulation Research (2017)

The use of risk markers has transformed cardiovascular medicine, exemplified by the routine assessment of troponin, for both diagnosis and assessment of prognosis in patients with chest pain. Clinical risk factors form the basis for risk assessment of cardiovascular disease and the addition of biochemical, cellular, and imaging parameters offers further refinement. Identifying novel risk factors may allow greater risk stratification and a steady, but gradual progression toward precision medicine. Indeed, the generation of data in this area of research is explosive and when combined with new technologies and techniques provides the potential for more refined, targeted approaches to cardiovascular medicine. Although discussing the most recent developments in this field, this review article aims to strike a balance between novelty and validity by focusing on recent large sample-size studies that have been validated in a separate cohort in most cases. Risk markers related to atherosclerosis, thrombosis, inflammation, cardiac injury, and fibrosis are introduced in the context of their pathophysiology. Rapidly developing new areas, such as assessment of micro-RNA, are also explored. Subsequently the prognostic ability of these risk markers in coronary artery disease, heart failure, and atrial fibrillation is discussed in detail.
P3.02c-045 Experience with Nivolumab in Compassionate Use in Non-Small Lung Carcinoma Patients Who Have Progressed to One or More Prior Lines of Chemotherapy
Authors: Paula Ribera Fernandez, Maria Marin Alcala, Juan Carlos Pardo Ruiz, Yolanda Garcia Garcia, Ismael Macias, Marta Ferrer Cardona
Journal: Journal of Thoracic Oncology (2017)
David Oliver: Improving access to intermediate care
Authors: David Oliver
Journal: BMJ (2017)

NHS Benchmarking’s national audit of intermediate care is in its fourth year. The 2015 round described over 340 services from 95 providers in England and 53 clinical commissioning groups.1 In the context of current system challenges it provides crucial data, especially on older people’s services. The median age of patients described is 82.

What do we mean by intermediate care models? The Department of Health’s Halfway Home report said in 2009, “Intermediate care is a range of integrated services to promote faster recovery from illness, prevent unnecessary acute hospital admission and premature admission to long-term residential care, support …
Mutations Targeting the ErbB Pathway and MSC in Peripheral T-Cell Lymphoma
Authors: Michael T Zimmermann, Surendra Dasari, Rebecca L Boddicker, Yu Zeng, Bruce Eckloff, Julie M Cunningham, Yanhong Wu, Julie C Porcher, Brian K Link, Stephen Ansell, James R Cerhan, Jean-Pierre Kocher, Andrew L Feldman
Journal: Blood (2015)
Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial
Authors: Marianna Christodoulou, Fiona Blackhall, Hitesh Mistry, Ahmet Leylek, Joost Knegjens, Vincent Remouchamps, Isabelle Martel-Lafay, Núria Farré, Matjaž Zwitter, Delphine Lerouge, Nicolas Pourel, Henri Janicot, Arnaud Scherpereel, Caroline Tissing-Tan, Karin Peignaux, Xavier Geets, Krzysztof Konopa, Corinne Faivre-Finn
Journal: Journal of Thoracic Oncology (2018)

There is a lack of data on the efficacy and safety of concurrent chemoradiotherapy in elderly, limited-stage, patients with SCLC.We compared outcomes of patients 70 years of age or older versus younger patients within the Concurrent Once-daily Versus twice-daily RadioTherapy (CONVERT) trial. Patients were randomized to receive 45 Gy/30 twice-daily fractions/19 days or 66 Gy/33 once-daily fractions/45 days concurrently with platinum-based chemotherapy. Overall survival and progression-free survival were evaluated using Kaplan-Meier methodology and Cox proportional hazards regression.Of 547 patients randomized between April 2008 and November 2013, 57 did not receive protocol treatment and were excluded. Of the 490 patients included, 67 (14%) were 70 years of age or older (median age: 73 years; range: 70-82). Fewer older patients received the optimal number of radiotherapy fractions (73% versus 85%; p = 0.03); however, chemotherapy compliance was similar in both groups (p = 0.24). Neutropenia grade 3/4 occurred more frequently in the elderly (84% versus 70%; p = 0.02) but rates of neutropenic sepsis (4% versus 7%; p = 0.07) and death (3% versus 1.4%; p = 0.67) were similar in both groups. With a median follow-up of 46 months; median survival in the elderly versus younger groups was 29 (95% confidence interval [CI]: 21-39) versus 30 months (95% CI: 26-35), respectively; (hazard ratio: 1.15, 95% CI: 0.84-1.59; p = 0.38). Median time to progression in the elderly versus younger groups was 18 months (95% CI: 13-31) versus 16 months (95% CI: 14-19), respectively (hazard ratio: 1.04, 95% CI: 0.76-1.41; p = 0.81).Concurrent chemoradiotherapy with modern radiotherapy techniques should be a treatment option for fit, older patients.
P2.01-056 Distinct PD-L1 Expression in Different Components of Pulmonary Sarcomatoid Carcinoma and Its Association with MET Mutation
Authors: Janaki Sharma, Alain Borczuk, Huijie Liu, Shenduo Li, Roman Perez-Soler, Balazs Halmos, Haiying Cheng
Journal: Journal of Thoracic Oncology (2017)
P2.03b-031 Impact of PD-L1 Status on Clinical Response in SELECT-1: Selumetinib + Docetaxel in KRASm Advanced NSCLC
Authors: Pasi Jänne, Michel Van Den Heuvel, Fabrice Barlesi, Manuel Cobo, Julien Mazieres, Lucio Crinò, Sergey Orlov, Fiona Blackhall, Jürgen Wolf, Pilar Garrido, Gabriella Mariani, Artem Poltoratskiy, Dana Ghiorghiu, Astrid Mckeown, Elaine Kilgour, Helen Angell, Paul Smith, Alexander Kohlmann, David Lawrence, Karin Bowen, Johan Vansteenkiste
Journal: Journal of Thoracic Oncology (2017)
P69 Evaluation of the STOPBANG threshold in the pre-operative screening for obstructive sleep apnoea at sherwood forest hospitals foundation trust
Authors: A Reynor, AW Molyneux, SD Tilbrook, RB Dean, E Crookes, J Tansley, NJ Ali
Journal: Thorax (2016)

<h3>Background</h3> Undiagnosed Obstructive Sleep Apnoea (OSA) has been associated with a higher perioperative morbidity and mortality. The aim of this study is to prepare a comprehensive review of the STOPBANG score, a pre-operative screening tool for patients with possible OSA. This study investigates if the current STOPBANG threshold of ≥3/8 is appropriate, or if it should be increased to ≥5/8 or ≥4/8 (with ¾ in the STOP category) to avoid the unnecessary cancellation/postponement of surgery and inappropriate referrals into the sleep service. <h3>Methods</h3> This was a retrospective study of patients referred to the Sleep Service following a positive STOPBANG score (≥3). The Research and Development Department of the hospital deemed the study did not require ethical approval. 84 patients were included in the study. The selected patients’ case notes were used to review their STOPBANG score, Epworth Sleepiness Score, type of sleep study performed, Oxygen Desaturation Index (ODI), diagnosis and treatment. If the patient had an ODI ≥ 15, or was successfully started on treatment with a borderline ODI &gt; 5 &lt; 15, this was considered an appropriate referral for that threshold. The sensitivity and specificity of the different STOPBANG thresholds were calculated to assess if the threshold score of STOPBANG ≥3 is appropriate, or if this should be adjusted to more appropriately identify those patients with OSA. <h3>Results</h3> For a threshold of ≥3, the sensitivity is very high (100%). The sensitivity is decreased for the threshold of ≥5 (71%), and further decreased for the ≥4/8 (3 from STOP) threshold (53%). For the ≥3 threshold, the specificity is 0%. The specificity is dramatically increased for the ≥5 threshold (70%), and highest in the ≥4/8 (3 from STOP) category (85%). <h3>Conclusion</h3> The statistical analysis confirms that a threshold of ≥3 has a very high sensitivity, but very low specificity. A threshold of ≥5 has a lower sensitivity however is much more specific and may be a more useful way of identifying the high risk of OSA surgical patient. A change in protocol to ≥5 aims to reduce the unnecessary delay or cancellation of surgery and avoid inappropriate referrals into the Respiratory and Sleep department.
OA15.06 The Efficacy of Lung Volume Analyzer for Measuring Resection Margin in Pulmonary Segmentectomy for Malignant Diseases
Authors: Yasuo Sekine, Takamasa Yun, Takahide Toyoda, Daisuke Kaiho, Eitetsu Koh, Toshiko Kamata
Journal: Journal of Thoracic Oncology (2017)
CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial
Authors: Julia von Tresckow, Paula Cramer, Jasmin Bahlo, Anja Engelke, Petra Langerbeins, Anna-Maria Fink, Holger Klaproth, Eugen Tausch, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Stephan Stilgenbauer, Sebastian Boettcher, Barbara Eichhorst, Michael Hallek
Journal: Blood (2015)
Epo Receptor Circuits to Irs2, Foxo3a, Trb3 and Bim1 Expression, and Erythroblast Survival.
Authors: Olga Bogacheva, Oleg Bogachev, Pradeep Sathyanarayana, Madhu P. Menon, William S. Kapelle, Estelle Houde, Don M. Wojchowski
Journal: Blood (2006)
Survival after Autologous Transplantation to Treat Diffuse Large B-Cell Lymphoma with a History of CNS Involvement, Bone Marrow Involvement, or Histologic Transformation.
Authors: Brandon Hayes-Lattin, Pritesh Mehta, Adam Dunn, Nan Subbiah, Jose F. Leis, Aleksandra Simic, Bryon Allen, Suzanne Balliesen, Peter T. Curtin, Elliot Epner, William H. Fleming, Carol Jacoby, Michael J. Mauro, Craig R. Nichols, Susan Schubach, Richard T. Maziarz
Journal: Blood (2004)
Allogeneic Transplantation Following Reduced Intensity Conditioning with Fludarabine and Melphalan In Patients with Advanced Myelofibrosis Is Associated with Unacceptable Rates of Acute Graft-Vs-Host Disease and Non-Relapse Mortality.
Authors: Samith Thomas Kochuparambil, Kavita Natrajan, Anand P. Jillella, Sayed Mehdi Hamadani, Farrukh Awan
Journal: Blood (2010)